Prescriber treatment patterns for tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin (mTOR) inhibitors in patients with renal cell carcinoma.
Clear cell renal cell carcinoma (RCC) is the most common histological subtype of malignant kidney tumors. Clinically, clear cell RCC cannot be distinguished from other histological RCC classes based ...
The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, discussing three abstracts, “Belzutifan + lenvatinib versus cabozantinib for ...
First described in 1985, chromophobe RCC accounts for approximately 5% of renal tumors.15 This RCC subtype has a better prognosis than either clear cell or papillary RCC, but it is worth noting that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results